1. The influence of peroxisome proliferator-activated receptor γ (PPARγ) ligands on cancer cell tumorigenicity
   Saghar Yousefnia et al, 2018, Gene CrossRef
2. Research Advances in the Correlation between Peroxisome Proliferator-Activated Receptor-γ and Digestive Cancers
   Shuqi Xu et al, 2018, PPAR Research CrossRef
3. Pioglitazone inhibits growth of human retinoblastoma cells via regulation of NF-κB inflammation signals
   Fengyun Wang et al, 2017, Journal of Receptors and Signal Transduction CrossRef
4. Rosiglitazone elevates sensitization of drug-resistant oral epidermoid carcinoma cells to vincristine by G2/M-phase arrest, independent of PPAR-γ pathway
   Hong-Yuan Wang et al, 2016, Biomedicine & Pharmacotherapy CrossRef
5. Prevention and treatment of cancer targeting chronic inflammation: research progress, potential agents, clinical studies and mechanisms
   Yong Zhang et al, 2017, Sci. China Life Sci. CrossRef
6. Drug Repurposing for Retinoblastoma: Recent Advances
   Kamakshi Dandu et al, 2019, CTMC CrossRef
7. Identification of Crucial Genetic Factors, Such as PPARγ, that Regulate the Pathogenesis of Fatty Liver Disease in Dairy Cows Is Imperative for the Sustainable Development of Dairy Industry
   Kerong Shi et al, 2020, Animals CrossRef
8. FAM3A mediates PPARγ's protection in liver ischemia-reperfusion injury by activating Akt survival pathway and repressing inflammation and oxidative stress
   Zhenzhen Chen et al, 2017, Oncotarget CrossRef
9. Combination treatment strategies with a focus on rosiglitazone and adriamycin for insulin resistant liver cancer
   Yi-Fan Dang et al, 2020, Journal of Drug Targeting CrossRef
10. An immunogenomic signature for molecular classification in hepatocellular carcinoma
    Weiwei Zhuang et al, 2021, Molecular Therapy - Nucleic Acids CrossRef
11. PPARs as Metabolic Sensors and Therapeutic Targets in Liver Diseases
    Hugo Christian Monroy-Ramirez et al, 2021, IJMS CrossRef
12. Design, Molecular Docking, Synthesis, Anticancer and Anti-Hyperglycemic Assessments of Thiazolidine-2,4-Diones Bearing Sulfonylthiourea Moieties as Potent VEGFR-2 Inhibitors and PPARγ Agonists
    Mohamed A. Abdelgawad et al, 2022, Pharmaceuticals CrossRef
13. Peroxisome proliferator-activated receptor gamma as a therapeutic target for hepatocellular carcinoma: Experimental and clinical scenarios
    Swati Katoch et al, 2022, WJG CrossRef
14. New 4-thiazolidinone-based molecules Les-2769 and Les-3266 as possible PPARγ modulators
    Monika Bar et al, 2022, Bioorganic Chemistry CrossRef
15. Therapeutic targets for metabolic dysfunction-associated steatotic liver disease and their roles in hepatocellular carcinoma
    Chenyu Wei et al, 2023, Explor Dig Dis CrossRef
16. KGCN-DDA: A Knowledge Graph Based GCN Method for Drug-Disease Association Prediction
    Hongyu Kang et al, 2024 CrossRef
17. Electroacupuncture activates the peroxisome proliferators‐activated receptor pathway to improve the phenotype of cerebral palsy
    Zhi‐Feng Wu et al, 2024, CNS Neurosci Ther CrossRef
18. In silico and cheminformatics prediction with experimental validation of an adipogenesis cocktail, sorafenib with rosiglitazone for HCC dedifferentiation
    Aya Anis et al, 2024, Journal of Genetic Engineering and Biotechnology CrossRef